Literature DB >> 6229578

Immunoglobulin production by human peripheral lymphocytes induced by anti-C3 receptor antibodies.

M R Daha, A C Bloem, R E Ballieux.   

Abstract

The exact function of receptors for C3b (CR1), which are present on B lymphocytes, is not clear. The present studies were performed to determine the influence of heterologous anti-CR1 on the production of IgM, IgG, and IgA by human peripheral B lymphocytes in vitro. Anti-CR1, raised in rabbits by immunization with purified erythrocyte CR1, was rendered immunospecific and was converted to F(ab')2 and Fab' by enzyme digestion. Pre-immune F(ab')2 and Fab' served as controls. Normal human blood T lymphocytes and T cell-depleted mononuclear cells were cultured for 6 days in RPMI medium and 10% heated fetal calf serum with a low dose (7 micrograms/ml) of pokeweed mitogen (PWM) alone or with PWM and F(ab')2-anti-CR1. In control experiments the effects of F(ab')2-anti-CR1 without PWM and of pre-immune F(ab')2, Fab'-anti-CR1 and pre-immune Fab' in combination with PWM were also tested. When PWM and F(ab')2-anti-CR1 were present simultaneously, 4.3 X 10(3), 2.5 X 10(3), and 1.8 X 10(3) ng/ml of IgM, IgG, and IgA were synthesized, respectively, in cultures containing 4.5 X 10(5) mononuclear blood cells. All other combinations resulted in synthesis of less than 250 ng/ml of each class of Ig. The presence of purified CR1 in the cultures containing PWM and F(ab')2-anti-CR1 caused a dose-dependent decrease of Ig synthesis. By culturing B cells isolated by E-C3b rosetting with T cells and monocytes, the anti-CR1 responding population was demonstrated to be mainly in the CR1-rich B cell fraction. Fab'-anti-CR1 at high doses was also able to stimulate Ig production in the presence of low concentrations of PWM. These data suggest that triggering of CR1 on B cells results in modulation of antibody production and that triggering of CR1 with more than one antibody is required for an optimal response.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6229578

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

Review 1.  Functional B-lymphocyte surface antigens.

Authors:  J T Golay
Journal:  Immunology       Date:  1986-09       Impact factor: 7.397

2.  Soluble form of complement C3b/C4b receptor (CR1) results from a proteolytic cleavage in the C-terminal region of CR1 transmembrane domain.

Authors:  I Hamer; J P Paccaud; D Belin; C Maeder; J L Carpentier
Journal:  Biochem J       Date:  1998-01-01       Impact factor: 3.857

3.  Complement-activating ability of leucocytes from patients with complement factor I deficiency.

Authors:  H V Marquart; J M Rasmussen; R G Leslie
Journal:  Immunology       Date:  1997-07       Impact factor: 7.397

4.  Mitogenic stimulation of malignant B cells Waldenstrøm's macroglobulinaemia: secretion of monoclonal IgM by in vitro-induced plasmablasts.

Authors:  A C Bloem; M A Chand; B van Camp; E J Bast; R E Ballieux
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

5.  Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2.

Authors:  J D Fingeroth; J J Weis; T F Tedder; J L Strominger; P A Biro; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

Review 6.  CR1 and the cell membrane proteins that bind C3 and C4. A basic and clinical review.

Authors:  J G Wilson; N A Andriopoulos; D T Fearon
Journal:  Immunol Res       Date:  1987       Impact factor: 2.829

7.  C3b receptor (CR1) on phagocytic cells from SLE patients: analysis of the defect and familial study.

Authors:  A Mir; F Porteu; M Levy; P Lesavre; L Halbwachs-Mecarelli
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

8.  Autoantibody to the C3b/C4b receptor and absence of this receptor from erythrocytes of a patient with systemic lupus erythematosus.

Authors:  J G Wilson; R M Jack; W W Wong; P H Schur; D T Fearon
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

9.  Normal C3b receptor (CR1) genomic polymorphism in patients with insulin-dependent diabetes mellitus (IDDM): is the low erythrocyte CR1 expression an acquired phenomenon?

Authors:  P E Ruuska; I Ikäheimo; S Silvennoinen-Kassinen; M L Käär; A Tiilikainen
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

10.  C3b receptor (CR1) genomic polymorphism in rheumatoid arthritis. Low receptor levels on erythrocytes are an acquired phenomenon.

Authors:  A Kumar; A N Malaviya; S Sinha; P S Khandekar; K Banerjee; L M Srivastava
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.